Pulmonary Arterial Hypertension Market Global - Market Size, Share, Trends, Growth Drivers, Development and Forecasts Analysis 2015-2019 adds "Global Pulmonary Arterial Hypertension (PAH)) Market: Trends and Opportunities (2015-2019)" report to its research store.

The report titled “Global PAH Market: Trends and Opportunities (2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.

The report provides detailed analysis of the global Pulmonary Arterial Hypertension market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report.

The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.

Company Coverage
• Actelion Limited
• United Therapeutics Limited
• SteadyMed Limited

PAH Drug Mechanism
• Endothelin Receptor Antagonists (ERA)
• PDE 5 Inhibitors
• Prostacyclins
• sGC Stimulator

Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.

Purchase a copy of “Pulmonary Arterial Hypertension Market” research report at USD 800 (Single User License)

In 2001, the US Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. Actelion develop the Tracleer and the sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015.

Despite an increase in per-member-per-year spend from 2013 to 2014; trend for medications used to treat pulmonary hypertension is expected to be sluggish again in 2015, chiefly because of the market saturation of generic sildenafil. The global PAH market is expected to achieve highest sales till now in the year 2017 due to imminent release of the PAH drug called Uptravi (Selexipag) in 2016, which is anticipated to potentially drive the growth of the total market till 2019. Popularity of combinational therapies is also likely to drive the market in the aforementioned period.

Few points from List of Tables and Figures of Pulmonary Arterial Hypertension Market:

List of Tables

Table 1: PAH Survival Rates, 2014
Table 2: Cost of PAH Treatment
Table 3: Trevyent vs. Remodulin
Table 4: Competitive Landscape of PAH Market Key Players, 2014
Table 5: PAH Endothelin Antagonist Drug Comparison
Table 6: PAH PDE5 Inhibitor Drug Comparison
Table 7: PAH Prostacyclin Drug Comparison
Table 8: PAH sCG Stimulator Drug
Table 9: Actelion Development Pipeline
Table 10: Financial Overview of SteadyMed; 2012-2014

List of Figures

Figure 1: Pulmonary Circulation of a PAH Patient vs. an Unaffected Person
Figure 2: PAH Treatment Schedule by Disease Severity
Figure 3: PAH Diagnoses
Figure 4: PAH Associated with Other Diseases (APAH)
Figure 5: Global PAH Market by Value; 2010-2014 (US$ Billion)
Figure 6: Global PAH Market by Value Forecast; 2015-2019 (US$ Billion)
Figure 7: Global Endothelin Receptor Antagonists (ERA) Market by Value; 2010-2014 (US$ Million)
Figure 8: Global Endothelin Receptor Antagonists (ERA) Market by Value Forecast; 2015-2019 (US$ Million)
Figure 9: Global PDE 5 Inhibitors Market by Value; 2010-2014 (US$ Million)
Figure 10: Global PDE 5 Inhibitors Market by Value Forecast; 2015-2019 (US$ Million)

Other Related Reports on Pharmaceuticals Market:

Global Human Growth Hormone Market Report: 2015 Edition ( The global HGH report discusses the key ongoing trends like global agreement for Long-Acting Human Growth Hormone (HGH-CTP), increasing use of biosimilar version of drugs and continuous growth of recombinant growth hormones market. On the industry development front, the current inclination is towards developing better treatments for Alzheimer’s disease and advancements in needle free injections technology.

Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition ( Iron deficiency anemia is the most common form of anemia throughout the world. It is estimated that two billion people suffer from iron deficiency anemia worldwide. To address iron deficiency, iron therapy is important being the critical factor in the production of red blood cells. Around 4.5 million Americans are diagnosed and suffering from iron deficiency anemia (IDA).

Global Hemophilia Market Report: 2015 Edition (
The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

Research on China Anesthetic Industry , 2015 at

Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars at

About Us:
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Us:
Ritesh Tiwari
Corporate Office
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: + 1 888 391 5441